Title
Category
Credits
Event date
Cost
AI-Powered Transplant Success: Optimizing Organ Allocation
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore the ways in which artificial intelligence (AI) can improve organ allocation and transplantation medicine. This session will delve into how AI-driven algorithms enhance organ-matching precision, help predict transplant outcomes and optimize postoperative care. Participants will gain insight into the practical integration of AI into transplant practices, learn innovative strategies, and discuss real-world examples that demonstrate improved patient care and improve transplant success rates.
New Insights into the Development, Treatment and Repair of Aortic Aneurysms
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity will delve into the genetic predispositions and environmental factors contributing to the formation of aortic aneurysms (AA) and how these insights are leading to personalized treatment strategies. It will focus on advancements in screening, diagnosis and treatment, including ongoing research into new therapies such as intravenous immune-modulating cells that can potentially reduce aneurysm size.
Personalized Medicine in Inflammatory Bowel Disease Management
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
Join us to explore the role of personalized medicine in the management of inflammatory bowel disease (IBD), including the genetic and environmental factors that contribute to this disease. The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) framework of evidence- and consensus-based recommendations for IBD treatment strategies will be reviewed, and the significance of biomarkers in guiding individualized therapy will be highlighted, with a focus on emerging therapies such as JAK inhibitors and S1P receptor modulators.
Understanding Co-occurring Eating Disorders and PTSD: Prevalence, Presentation, and Treatment
  • Behavioral health
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
Research suggests that high comorbidity exists between eating disorders (EDs) and PTSD. In fact, some studies report that up to 90% of individuals suffering from EDs have experienced at least one traumatic event in their lifetime. Those who enter ED treatment with co-occurring PTSD tend to exhibit more severe eating disorder pathology, poorer treatment outcomes, and higher relapse rates compared to those without PTSD. Historically, evidence-based treatment models for EDs have primarily focused on addressing ED symptoms and behaviors, often overlooking co-occurring psychological conditions such as PTSD. However, in recent years, there has been growing recognition within the field of eating disorder treatment of the limitations of this approach. As a result, there is increasing emphasis on integrating evidence- based PTSD treatments into ED treatment to better support individuals with this dual diagnosis. This activity will explore the intersection of EDs and trauma, examine what current research reveals about their co-occurrence and discuss strategies for effectively addressing this complex comorbidity within treatment settings.
Care Management Roles in Identifying and Mitigating Social Drivers of Health
  • Case management
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
Social Drivers of Health (SDoH) are the effects of unidentified or poorly controlled conditions related to how our health and well-being are impacted. With early identification and mitigation of SDoH the care management professional can significantly impact various non-healthcare related limitations, instabilities, and barriers that influence patient outcomes. This learning activity will provide Care Management professionals with resources aimed at assisting patients in limiting health disparities, resulting in living healthier lives.
EAP 101 for Behavioral Health Providers
  • Behavioral health
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
This activity will provide an overview of the EAP field, history and expansion of services and components of EAP services, and review EAPA standards and code of ethics. The difference between EAP and behavioral health will be examined along with the types of EAP referrals, the benefits of EAP services and the management referral process. EAP core technology, CEAP (certification) and dual relationships will also be discussed.
Heart Failure at the Crossroads: Early Recognition and Proactive Management
  • Disease management
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
Heart failure remains a leading cause of hospitalization and mortality. This session focuses on recognizing early signs, diagnostic tools, and evidence-based strategies to optimize care, improve patient quality of life, and reduce readmissions.
GLP-1 Agonists in Practice: A New Era in Obesity and Diabetes Management
  • Disease management
  • Wellness
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
GLP-1 receptor agonists have reshaped the landscape of obesity and type 2 diabetes management, offering benefits beyond glycemic control. This session explores their mechanisms, clinical applications, and emerging evidence on their implications for broader metabolic care and in the treatment of obesity-related conditions such as obstructive sleep apnea.
Gene Therapy in the Genomic Era: Promise, Progress and Patient Impact
  • Disease management
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
Gene therapy technologies are revolutionizing treatment for genetic diseases. This session explores the science, clinical applications, and patient perspectives, with a focus on sickle cell disease and emerging technologies like CRISPR.
COPD in 2025: Early Detection, Diagnostic Precision, and Emerging Therapies
  • Disease management
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
This session explores the latest updates in the diagnosis and management of chronic obstructive pulmonary disease (COPD) as outlined in the 2025 GOLD Report. Early case finding, refined spirometry protocols and novel therapeutic options are discussed, along with the importance of pre-bronchodilator spirometry, strategies for early detection in at-risk populations, and the integration of new treatments into updated treatment algorithms.

Pages